Skip to main content
Erschienen in: Journal of NeuroVirology 4/2016

01.08.2016

Predictors and characteristics of seizures in survivors of progressive multifocal leukoencephalopathy

verfasst von: Dhanashri P. Miskin, Susan T. Herman, Long H. Ngo, Igor J. Koralnik

Erschienen in: Journal of NeuroVirology | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

This study aims to determine the risk factors for epileptogenesis and characteristics of seizures in patients with progressive multifocal leukoencephalopathy (PML) who survive more than 1 year from onset of neurological symptoms (PML survivors). We reviewed clinical data including seizure history and MR imaging studies from PML survivors evaluated at our institution between 1997 and 2014. PML progressors who passed away within 1 year and patients with a history of seizures prior to PML diagnosis were excluded from the analysis. Of 64 PML survivors, 28 (44 %) developed seizures. The median time from the onset of PML symptoms to the first seizure was 5.4 months (range 0–159) and 64 % of patients with seizures had them within the first year. The presence of juxtacortical PML lesions was associated with a relative risk of seizures of 3.5 (p < 0.02; 95 % confidence interval (CI) 1.3–9.4) in multivariate analyses. Of all seizure types, 86 % were focal and 60 % most likely originated from the frontal lobes. Among seizure patients, 89 % required treatment, including one (54 %), two (25 %), or three (10.5 %) antiepileptic drugs. Seizures are a frequent complication in PML and can develop throughout the entire course of the disease. However, late onset seizures did not signify PML relapse. Seizures may require treatment with multiple antiepileptic medications and are a significant co-morbidity in PML.
Literatur
Zurück zum Zitat Bartsch T, Rempe T, Wrede A, Leypoldt F, Adams O, Rohr A, Jansen O, Bruck W, Wuthrich C, Deuschl G, Koralnik IJ (2015) Progressive hemiparesis in a psoriasis patient treated with dimethyl fumarate. Ann Neurol 78:501–14CrossRefPubMed Bartsch T, Rempe T, Wrede A, Leypoldt F, Adams O, Rohr A, Jansen O, Bruck W, Wuthrich C, Deuschl G, Koralnik IJ (2015) Progressive hemiparesis in a psoriasis patient treated with dimethyl fumarate. Ann Neurol 78:501–14CrossRefPubMed
Zurück zum Zitat Beghi E, Carpio A, Forsgren L, Hesdorffer DC, Malmgren K, Sander JW, Tomson T, Hauser WA (2010) Recommendation for a definition of acute symptomatic seizure. Epilepsia 51:671–675CrossRefPubMed Beghi E, Carpio A, Forsgren L, Hesdorffer DC, Malmgren K, Sander JW, Tomson T, Hauser WA (2010) Recommendation for a definition of acute symptomatic seizure. Epilepsia 51:671–675CrossRefPubMed
Zurück zum Zitat Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, Engel J, French J, Glauser TA, Mathern GW, Moshe SL, Nordli D, Plouin P, Scheffer IE (2010) Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia 51:676–685CrossRefPubMed Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, Engel J, French J, Glauser TA, Mathern GW, Moshe SL, Nordli D, Plouin P, Scheffer IE (2010) Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia 51:676–685CrossRefPubMed
Zurück zum Zitat Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, Sejvar JJ, Bartt R, Major EO, Nath A (2013) PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section. Neurology 80:1430–1438CrossRefPubMedPubMedCentral Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, Sejvar JJ, Bartt R, Major EO, Nath A (2013) PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section. Neurology 80:1430–1438CrossRefPubMedPubMedCentral
Zurück zum Zitat Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, Bennett CL (2009) Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 10:816–824CrossRefPubMed Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, Bennett CL (2009) Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 10:816–824CrossRefPubMed
Zurück zum Zitat Casado JL, Corral I, Garcia J, Martinez-San Millan J, Navas E, Moreno A, Moreno S (2014) Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV/AIDS patients in the current era. Eur J Clin Microbiol Infect Dis 33:179–187CrossRefPubMed Casado JL, Corral I, Garcia J, Martinez-San Millan J, Navas E, Moreno A, Moreno S (2014) Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV/AIDS patients in the current era. Eur J Clin Microbiol Infect Dis 33:179–187CrossRefPubMed
Zurück zum Zitat Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9:438–446CrossRefPubMed Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9:438–446CrossRefPubMed
Zurück zum Zitat Collazos J, Mayo J, Martinez E, Blanco MS (1999) Contrast-enhancing progressive multifocal leukoencephalopathy as an immune reconstitution event in AIDS patients. Aids 13:1426–1428CrossRefPubMed Collazos J, Mayo J, Martinez E, Blanco MS (1999) Contrast-enhancing progressive multifocal leukoencephalopathy as an immune reconstitution event in AIDS patients. Aids 13:1426–1428CrossRefPubMed
Zurück zum Zitat Dahlhaus S, Hoepner R, Chan A, Kleiter I, Adams O, Lukas C, Hellwig K, Gold R (2013) Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry 84:1068–1074CrossRefPubMedPubMedCentral Dahlhaus S, Hoepner R, Chan A, Kleiter I, Adams O, Lukas C, Hellwig K, Gold R (2013) Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry 84:1068–1074CrossRefPubMedPubMedCentral
Zurück zum Zitat Dammeier N, Schubert V, Hauser TK, Bornemann A, Bischof F (2015) Case report of a patient with progressive multifocal leukoencephalopathy under treatment with dimethyl fumarate. BMC Neurol 15:108CrossRefPubMedPubMedCentral Dammeier N, Schubert V, Hauser TK, Bornemann A, Bischof F (2015) Case report of a patient with progressive multifocal leukoencephalopathy under treatment with dimethyl fumarate. BMC Neurol 15:108CrossRefPubMedPubMedCentral
Zurück zum Zitat Du Pasquier RA, Koralnik IJ (2003) Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial? J Neurovirol 9(Suppl 1):25–31CrossRefPubMed Du Pasquier RA, Koralnik IJ (2003) Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial? J Neurovirol 9(Suppl 1):25–31CrossRefPubMed
Zurück zum Zitat Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Engel J Jr, Forsgren L, French JA, Glynn M, Hesdorffer DC, Lee BI, Mathern GW, Moshe SL, Perucca E, Scheffer IE, Tomson T, Watanabe M, Wiebe S (2014) ILAE official report: a practical clinical definition of epilepsy. Epilepsia 55:475–482CrossRefPubMed Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Engel J Jr, Forsgren L, French JA, Glynn M, Hesdorffer DC, Lee BI, Mathern GW, Moshe SL, Perucca E, Scheffer IE, Tomson T, Watanabe M, Wiebe S (2014) ILAE official report: a practical clinical definition of epilepsy. Epilepsia 55:475–482CrossRefPubMed
Zurück zum Zitat Gadzia J, Turner J (2010) Progressive multifocal leukoencephalopathy in two psoriasis patients treated with efalizumab. J Drugs Dermatol 9:1005–1009PubMed Gadzia J, Turner J (2010) Progressive multifocal leukoencephalopathy in two psoriasis patients treated with efalizumab. J Drugs Dermatol 9:1005–1009PubMed
Zurück zum Zitat Gheuens S, Bord E, Kesari S, Simpson DM, Gandhi RT, Clifford DB, Berger JR, Ngo L, Koralnik IJ (2011) Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome. J Virol 85:7256–7263CrossRefPubMedPubMedCentral Gheuens S, Bord E, Kesari S, Simpson DM, Gandhi RT, Clifford DB, Berger JR, Ngo L, Koralnik IJ (2011) Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome. J Virol 85:7256–7263CrossRefPubMedPubMedCentral
Zurück zum Zitat Gheuens S, Ngo L, Wang X, Alsop DC, Lenkinski RE, Koralnik IJ (2012a) Metabolic profile of PML lesions in patients with and without IRIS: an observational study. Neurology 79:1041–1048CrossRefPubMedPubMedCentral Gheuens S, Ngo L, Wang X, Alsop DC, Lenkinski RE, Koralnik IJ (2012a) Metabolic profile of PML lesions in patients with and without IRIS: an observational study. Neurology 79:1041–1048CrossRefPubMedPubMedCentral
Zurück zum Zitat Gheuens S, Smith DR, Wang X, Alsop DC, Lenkinski RE, Koralnik IJ (2012b) Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Neurology 78:1390–1393CrossRefPubMedPubMedCentral Gheuens S, Smith DR, Wang X, Alsop DC, Lenkinski RE, Koralnik IJ (2012b) Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Neurology 78:1390–1393CrossRefPubMedPubMedCentral
Zurück zum Zitat Gray F, Bazille C, Adle-Biassette H, Mikol J, Moulignier A, Scaravilli F (2005) Central nervous system immune reconstitution disease in acquired immunodeficiency syndrome patients receiving highly active antiretroviral treatment. J Neurovirol 11(Suppl 3):16–22CrossRefPubMed Gray F, Bazille C, Adle-Biassette H, Mikol J, Moulignier A, Scaravilli F (2005) Central nervous system immune reconstitution disease in acquired immunodeficiency syndrome patients receiving highly active antiretroviral treatment. J Neurovirol 11(Suppl 3):16–22CrossRefPubMed
Zurück zum Zitat Hoepner R, Ahlbrecht J, Faissner S, Schneider R, Dahlhaus S, Adams O, Raab P, Lukas C, Chan A, Stangel M, Gold R (2014) Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry 85:1177–1178CrossRefPubMed Hoepner R, Ahlbrecht J, Faissner S, Schneider R, Dahlhaus S, Adams O, Raab P, Lukas C, Chan A, Stangel M, Gold R (2014) Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry 85:1177–1178CrossRefPubMed
Zurück zum Zitat Hoffmann C, Horst HA, Albrecht H, Schlote W (2003) Progressive multifocal leucoencephalopathy with unusual inflammatory response during antiretroviral treatment. J Neurol Neurosurg Psychiatry 74:1142–1144CrossRefPubMedPubMedCentral Hoffmann C, Horst HA, Albrecht H, Schlote W (2003) Progressive multifocal leucoencephalopathy with unusual inflammatory response during antiretroviral treatment. J Neurol Neurosurg Psychiatry 74:1142–1144CrossRefPubMedPubMedCentral
Zurück zum Zitat Khatri BO, Garland J, Berger J, Kramer J, Sershon L, Olapo T, Sesing J, Dukic M, Rehn E (2015) The effect of dimethyl fumarate (Tecfidera) on lymphocyte counts: a potential contributor to progressive multifocal leukoencephalopathy risk. Mult Scler Relat Disord 4:377–379CrossRefPubMed Khatri BO, Garland J, Berger J, Kramer J, Sershon L, Olapo T, Sesing J, Dukic M, Rehn E (2015) The effect of dimethyl fumarate (Tecfidera) on lymphocyte counts: a potential contributor to progressive multifocal leukoencephalopathy risk. Mult Scler Relat Disord 4:377–379CrossRefPubMed
Zurück zum Zitat Khoury MN, Alsop DC, Agnihotri SP, Pfannl R, Wuthrich C, Ho ML, Hackney D, Ngo L, Anderson MP, Koralnik IJ (2014) Hyperintense cortical signal on magnetic resonance imaging reflects focal leukocortical encephalitis and seizure risk in progressive multifocal leukoencephalopathy. Ann Neurol 75:659–669CrossRefPubMedPubMedCentral Khoury MN, Alsop DC, Agnihotri SP, Pfannl R, Wuthrich C, Ho ML, Hackney D, Ngo L, Anderson MP, Koralnik IJ (2014) Hyperintense cortical signal on magnetic resonance imaging reflects focal leukocortical encephalitis and seizure risk in progressive multifocal leukoencephalopathy. Ann Neurol 75:659–669CrossRefPubMedPubMedCentral
Zurück zum Zitat Korman BD, Tyler KL, Korman NJ (2009) Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists. Arch Dermatol 145:937–942CrossRefPubMed Korman BD, Tyler KL, Korman NJ (2009) Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists. Arch Dermatol 145:937–942CrossRefPubMed
Zurück zum Zitat Kotecha N, George MJ, Smith TW, Corvi F, Litofsky NS (1998) Enhancing progressive multifocal leukoencephalopathy: an indicator of improved immune status? Am J Med 105:541–543CrossRefPubMed Kotecha N, George MJ, Smith TW, Corvi F, Litofsky NS (1998) Enhancing progressive multifocal leukoencephalopathy: an indicator of improved immune status? Am J Med 105:541–543CrossRefPubMed
Zurück zum Zitat Kothary N, Diak IL, Brinker A, Bezabeh S, Avigan M, Dal Pan G (2011) Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol 65:546–551CrossRefPubMed Kothary N, Diak IL, Brinker A, Bezabeh S, Avigan M, Dal Pan G (2011) Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol 65:546–551CrossRefPubMed
Zurück zum Zitat Lima MA, Koralnik IJ (2005) New features of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy and natalizumab. J Neurovirol 11(Suppl 3):52–57CrossRefPubMed Lima MA, Koralnik IJ (2005) New features of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy and natalizumab. J Neurovirol 11(Suppl 3):52–57CrossRefPubMed
Zurück zum Zitat Lima MA, Drislane FW, Koralnik IJ (2006) Seizures and their outcome in progressive multifocal leukoencephalopathy. Neurology 66:262–264CrossRefPubMed Lima MA, Drislane FW, Koralnik IJ (2006) Seizures and their outcome in progressive multifocal leukoencephalopathy. Neurology 66:262–264CrossRefPubMed
Zurück zum Zitat Marousi S, Travasarou M, Karageorgiou CE, Gheuens S, Koralnik IJ (2012) Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Neurology 79:2160, author reply 2160CrossRefPubMed Marousi S, Travasarou M, Karageorgiou CE, Gheuens S, Koralnik IJ (2012) Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Neurology 79:2160, author reply 2160CrossRefPubMed
Zurück zum Zitat Martinez JV, Mazziotti JV, Efron ED, Bonardo P, Jordan R, Sevlever G, Martinez M, Verbanaz SC, Salazar ZS, Pardal MF, Reisin R (2006) Immune reconstitution inflammatory syndrome associated with PML in AIDS: a treatable disorder. Neurology 67:1692–1694CrossRefPubMed Martinez JV, Mazziotti JV, Efron ED, Bonardo P, Jordan R, Sevlever G, Martinez M, Verbanaz SC, Salazar ZS, Pardal MF, Reisin R (2006) Immune reconstitution inflammatory syndrome associated with PML in AIDS: a treatable disorder. Neurology 67:1692–1694CrossRefPubMed
Zurück zum Zitat Miralles P, Berenguer J, Lacruz C, Cosin J, Lopez JC, Padilla B, Munoz L, Garcia-de-Viedma D (2001) Inflammatory reactions in progressive multifocal leukoencephalopathy after highly active antiretroviral therapy. Aids 15:1900–1902CrossRefPubMed Miralles P, Berenguer J, Lacruz C, Cosin J, Lopez JC, Padilla B, Munoz L, Garcia-de-Viedma D (2001) Inflammatory reactions in progressive multifocal leukoencephalopathy after highly active antiretroviral therapy. Aids 15:1900–1902CrossRefPubMed
Zurück zum Zitat Moll NM, Rietsch AM, Ransohoff AJ, Cossoy MB, Huang D, Eichler FS, Trapp BD, Ransohoff RM (2008) Cortical demyelination in PML and MS: similarities and differences. Neurology 70:336–343CrossRefPubMed Moll NM, Rietsch AM, Ransohoff AJ, Cossoy MB, Huang D, Eichler FS, Trapp BD, Ransohoff RM (2008) Cortical demyelination in PML and MS: similarities and differences. Neurology 70:336–343CrossRefPubMed
Zurück zum Zitat Nita DA, Cisse Y, Timofeev I, Steriade M (2006) Increased propensity to seizures after chronic cortical deafferentation in vivo. J Neurophysiol 95:902–913CrossRefPubMed Nita DA, Cisse Y, Timofeev I, Steriade M (2006) Increased propensity to seizures after chronic cortical deafferentation in vivo. J Neurophysiol 95:902–913CrossRefPubMed
Zurück zum Zitat Nuttall JJ, Wilmshurst JM, Ndondo AP, Yeats J, Corcoran C, Hussey GD, Eley BS (2004) Progressive multifocal leukoencephalopathy after initiation of highly active antiretroviral therapy in a child with advanced human immunodeficiency virus infection: a case of immune reconstitution inflammatory syndrome. Pediatr Infect Dis J 23:683–685CrossRefPubMed Nuttall JJ, Wilmshurst JM, Ndondo AP, Yeats J, Corcoran C, Hussey GD, Eley BS (2004) Progressive multifocal leukoencephalopathy after initiation of highly active antiretroviral therapy in a child with advanced human immunodeficiency virus infection: a case of immune reconstitution inflammatory syndrome. Pediatr Infect Dis J 23:683–685CrossRefPubMed
Zurück zum Zitat Okulicz JF, Grandits GA, French JA, George JM, Simpson DM, Birbeck GL, Ganesan A, Weintrob AC, Crum-Cianflone N, Lalani T, Landrum ML (2011) Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study. AIDS Res Ther 8:18CrossRefPubMedPubMedCentral Okulicz JF, Grandits GA, French JA, George JM, Simpson DM, Birbeck GL, Ganesan A, Weintrob AC, Crum-Cianflone N, Lalani T, Landrum ML (2011) Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study. AIDS Res Ther 8:18CrossRefPubMedPubMedCentral
Zurück zum Zitat Silva MT, Pacheco MC Jr, Vaz B (2006) Inflammatory progressive multifocal leukoencephalopathy after antiretroviral treatment. Aids 20:469–471CrossRefPubMed Silva MT, Pacheco MC Jr, Vaz B (2006) Inflammatory progressive multifocal leukoencephalopathy after antiretroviral treatment. Aids 20:469–471CrossRefPubMed
Zurück zum Zitat Tan K, Roda R, Ostrow L, McArthur J, Nath A (2009) PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 72:1458–1464CrossRefPubMedPubMedCentral Tan K, Roda R, Ostrow L, McArthur J, Nath A (2009) PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 72:1458–1464CrossRefPubMedPubMedCentral
Zurück zum Zitat Tan IL, McArthur JC, Clifford DB, Major EO, Nath A (2011) Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 77:1061–1067CrossRefPubMedPubMedCentral Tan IL, McArthur JC, Clifford DB, Major EO, Nath A (2011) Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 77:1061–1067CrossRefPubMedPubMedCentral
Zurück zum Zitat Topolnik L, Steriade M, Timofeev I (2003) Partial cortical deafferentation promotes development of paroxysmal activity. Cereb Cortex 13:883–893CrossRefPubMed Topolnik L, Steriade M, Timofeev I (2003) Partial cortical deafferentation promotes development of paroxysmal activity. Cereb Cortex 13:883–893CrossRefPubMed
Zurück zum Zitat Wuthrich C, Koralnik IJ (2012) Frequent infection of cortical neurons by JC virus in patients with progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol 71:54–65CrossRefPubMedPubMedCentral Wuthrich C, Koralnik IJ (2012) Frequent infection of cortical neurons by JC virus in patients with progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol 71:54–65CrossRefPubMedPubMedCentral
Zurück zum Zitat Xiong, W., Ping, X., Gao, J., Jin, X., 2011. Preparing undercut model of posttraumatic epileptogenesis in rodents. J Vis Exp Xiong, W., Ping, X., Gao, J., Jin, X., 2011. Preparing undercut model of posttraumatic epileptogenesis in rodents. J Vis Exp
Metadaten
Titel
Predictors and characteristics of seizures in survivors of progressive multifocal leukoencephalopathy
verfasst von
Dhanashri P. Miskin
Susan T. Herman
Long H. Ngo
Igor J. Koralnik
Publikationsdatum
01.08.2016
Verlag
Springer International Publishing
Erschienen in
Journal of NeuroVirology / Ausgabe 4/2016
Print ISSN: 1355-0284
Elektronische ISSN: 1538-2443
DOI
https://doi.org/10.1007/s13365-015-0414-3

Weitere Artikel der Ausgabe 4/2016

Journal of NeuroVirology 4/2016 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.